{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:27:27Z","timestamp":1782822447445,"version":"3.54.5"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.coviro.2024.101408","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T12:30:05Z","timestamp":1712147405000},"page":"101408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Inhaled aerosol viral-vectored vaccines against tuberculosis"],"prefix":"10.1016","volume":"66","author":[{"given":"Elena","family":"Stylianou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Satti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2024.101408_bib1","unstructured":"WHOrganisation:\u00a0Global Tuberculosis Report. Edited by; 2023."},{"key":"10.1016\/j.coviro.2024.101408_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.612675","article-title":"Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment","volume":"12","author":"Allue-Guardia","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2024.101408_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01134","article-title":"What have we learnt about BCG vaccination in the last 20 years?","volume":"8","author":"Dockrell","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2024.101408_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","article-title":"The efficacy of Bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature","volume":"96","author":"Colditz","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.coviro.2024.101408_bib6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2024.101408_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1238649","article-title":"Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2024.101408_sbref7","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11081304","article-title":"Next-Generation TB vaccines: progress, challenges, and prospects","volume":"11","author":"Zhuang","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.coviro.2024.101408_sbref8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2024.101408_sbref9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.coviro.2024.101408_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.molimm.2014.06.007","article-title":"A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice","volume":"62","author":"Li","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib12","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3892\/mmr.2015.3770","article-title":"Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice","volume":"12","author":"Li","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.coviro.2024.101408_sbref12","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","article-title":"Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis","volume":"173","author":"Wang","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-4614-6111-1_14","article-title":"Immunization strategies against pulmonary tuberculosis: considerations of T cell geography","volume":"783","author":"Horvath","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coviro.2024.101408_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/mi.2011.45","article-title":"Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge","volume":"5","author":"Bolton","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib16","doi-asserted-by":"crossref","first-page":"22213","DOI":"10.1073\/pnas.1015536108","article-title":"Genetic immunization in the lung induces potent local and systemic immune responses","volume":"107","author":"Song","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2024.101408_bib17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib18","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.4049\/jimmunol.0901937","article-title":"In a murine tuberculosis model, the absence of homeostatic chemokines delays granuloma formation and protective immunity","volume":"183","author":"Khader","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib19","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.apsb.2022.07.002","article-title":"Mucosal vaccine delivery: a focus on the breakthrough of specific barriers","volume":"12","author":"Huang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.coviro.2024.101408_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2024.101408_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41591-018-0319-9","article-title":"Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques","volume":"25","author":"Dijkman","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2024.101408_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0008-8749(02)00510-5","article-title":"CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis","volume":"216","author":"Saunders","year":"2002","journal-title":"Cell Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000392","article-title":"A critical role for CD8 T cells in a nonhuman primate model of tuberculosis","volume":"5","author":"Chen","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2024.101408_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2024.101408_bib26","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.4049\/jimmunol.1400019","article-title":"Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells","volume":"192","author":"Sakai","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib27","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.4049\/jimmunol.1201682","article-title":"Cutting edge: intravascular staining redefines lung CD8 T cell responses","volume":"189","author":"Anderson","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00992","article-title":"Lung tissue resident memory T-cells in the immune response to Mycobacterium tuberculosis","volume":"10","author":"Ogongo","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2024.101408_sbref28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142014","article-title":"Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung","volume":"131","author":"Ogongo","year":"2021","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coviro.2024.101408_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41385-020-0309-3","article-title":"Long-term maintenance of lung resident memory T cells is mediated by persistent antigen","volume":"14","author":"Uddback","year":"2021","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1189\/jlb.0313180","article-title":"Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection","volume":"95","author":"Wu","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.coviro.2024.101408_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","article-title":"The establishment of resident memory B cells in the lung requires local antigen encounter","volume":"20","author":"Allie","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib33","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.immuni.2022.03.003","article-title":"Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites","volume":"55","author":"MacLean","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2024.101408_bib34","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.jaci.2016.11.036","article-title":"Does size really matter?: relationship of particle size to lung deposition and exhaled fraction","volume":"139","author":"Jabbal","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102370","article-title":"Viral-vectored respiratory mucosal vaccine strategies","volume":"84","author":"Jeyanathan","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104298","article-title":"Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial","volume":"85","author":"Madhavan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coviro.2024.101408_bib37","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0264-410X(01)00471-6","article-title":"Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis","volume":"20","author":"Beyer","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087340","article-title":"The candidate TB vaccine, MVA85A, induces highly durable Th1 responses","volume":"9","author":"Tameris","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2024.101408_bib39","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2024.101408_sbref39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/CVI.00690-12","article-title":"Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques","volume":"20","author":"White","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coviro.2024.101408_sbref40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002790","article-title":"Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: a phase I randomised controlled trial","volume":"16","author":"Manjaly Thomas","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2024.101408_bib42","article-title":"Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults","volume":"9","author":"Riste","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"Ouedraogo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2024.101408_bib44","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2024.101408_bib45","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3018(20)30229-0","article-title":"Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1\/2a study","volume":"7","author":"Baden","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.coviro.2024.101408_bib46","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.4049\/jimmunol.1400676","article-title":"Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge","volume":"193","author":"Darrah","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135009","article-title":"AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in BCG-primed non-human primates","volume":"10","author":"Jeyanathan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2024.101408_bib48","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.vaccine.2021.01.034","article-title":"Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model","volume":"39","author":"Pinpathomrat","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib49","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00014-18","article-title":"Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine","volume":"86","author":"Stylianou","year":"2018","journal-title":"Infect Immun"},{"key":"10.1016\/j.coviro.2024.101408_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1263457","article-title":"A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge","volume":"14","author":"Stylianou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib52","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/mi.2015.29","article-title":"Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection","volume":"8","author":"Jeyanathan","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00623-z","article-title":"Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice","volume":"8","author":"Afkhami","year":"2023","journal-title":"NPJ Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0189-2","article-title":"Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques","volume":"5","author":"Vierboom","year":"2020","journal-title":"NPJ Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib55","article-title":"A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice","volume":"2","author":"Khan","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.coviro.2024.101408_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2017.00034","article-title":"Vesicular stomatitis virus-vectored multi-antigen tuberculosis vaccine limits bacterial proliferation in mice following a single intranasal dose","volume":"7","author":"Zhang","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.coviro.2024.101408_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127515","article-title":"Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice","volume":"14","author":"Kirk","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2024.101408_bib58","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ymthe.2017.02.018","article-title":"Sendai virus mucosal vaccination establishes lung-resident memory CD8 T cell immunity and boosts BCG-primed protection against TB in mice","volume":"25","author":"Hu","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2024.101408_bib59","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1016\/j.vaccine.2011.09.028","article-title":"Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies","volume":"29","author":"Moriya","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib60","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2004.01.053","article-title":"Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults","volume":"22","author":"Slobod","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087439","article-title":"Preclinical evaluation of TB\/FLU-04L-An intranasal influenza vector-based boost vaccine against tuberculosis","volume":"24","author":"Shurygina","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coviro.2024.101408_bib62","article-title":"Mucosal influenza vector vaccine carrying TB10.4 and HspX antigens provides protection against Mycobacterium tuberculosis in mice and Guinea pigs","volume":"9","author":"Sergeeva","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib63","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.vaccine.2013.11.108","article-title":"Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization","volume":"32","author":"Watanabe","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib64","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1016\/j.vaccine.2008.03.101","article-title":"Intratracheal administration of third-generation lentivirus vector encoding MPT51 from Mycobacterium tuberculosis induces specific CD8+ T-cell responses in the lung","volume":"26","author":"Hashimoto","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2024.101408_bib65","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/imm.12498","article-title":"Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis Bacillus Calmette-Guerin challenge in mice","volume":"146","author":"Britton","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.coviro.2024.101408_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111142","article-title":"A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4(+) T cell immunity","volume":"40","author":"Lopez","year":"2022","journal-title":"Cell Rep"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625724000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625724000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T01:37:57Z","timestamp":1717465077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625724000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":66,"alternative-id":["S1879625724000221"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2024.101408","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled aerosol viral-vectored vaccines against tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2024.101408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101408"}}